Truveta Data: 40% of Early Foundayo Users Had No Prior GLP-1 Use
Image
United States – October 27, 2026 -- An analysis of 5,723 patients on Foundayo (oral orforglipron) found that 40.3% had no evidence of prior GLP-1 medication use, according to Truveta, which is pitching real-time "healthcare intelligence" to life science, healthcare and government teams.
Foundayo uptake runs mostly through primary care
Truveta researchers used Truveta Data to identify patients with a Foundayo prescription or medication dispense between April 1 and July 6, 2026. The drug was approved for obesity in April 2026.
General practice clinicians accounted for 60.0% of prescriptions, and advanced practice providers for another 31.9%. Only 0.1% of patients had evidence of recent oral semaglutide use.